STOCK TITAN

Zentek Ltd - ZTEK STOCK NEWS

Welcome to our dedicated news page for Zentek (Ticker: ZTEK), a resource for investors and traders seeking the latest updates and insights on Zentek.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zentek's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zentek's position in the market.

Rhea-AI Summary
Zentek Ltd. announces successful preclinical testing of its C19HBA aptamer as a potential therapeutic for SARS-CoV-2, outperforming a leading monoclonal antibody in trials. The aptamer demonstrated improved therapeutic benefits in mice, showing signs of recovery one day earlier and a 30% reduction in total average weight loss compared to the control groups. The company plans to move C19HBA towards phase 1 clinical trials for COVID-19 and explore other potential partnerships for the platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.8%
Tags
none
-
Rhea-AI Summary
Zentek Ltd. announces the completion of a study demonstrating significant energy, emission, and cost savings for commercial buildings adopting ZenGUARDTM Enhanced Air Filters. The study revealed that using ZenGUARDTM filters can reduce HVAC energy consumption by approximately 62%, resulting in monetary savings of approximately $12,400 per year and avoidance of 32 tonnes of CO2 emissions per year for each office space. The company estimates that energy consumption within the Canadian Federal Public Service could be reduced by 455.7 million kWh, translating to monetary savings of $68.4 million per year and an avoidance of approximately 58,200 tonnes of CO2 emissions per year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Zentek Ltd. announces the resignation of Dr. Francis Dubé as Chairman of the Board, appointing Mr. Eric Wallman as the new Chairman. Mr. Wallman, an independent director since 2018, will uphold best governance practices. Dr. Dubé will continue as a director and Chief Operating Officer. CEO Greg Fenton expresses gratitude towards Dr. Dubé and Mr. Wallman for their roles in governance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Rhea-AI Summary
Zentek Ltd. (ZTEK) announces the launch of Triera Biosciences Ltd. as its wholly owned subsidiary for aptamer platform technology. Triera will focus on developing a treatment for the SARS-CoV-2 virus, including the Omicron XBB 1.5 variant, and a rapid detection platform. The company aims to create a standalone entity to attract potential pharmaceutical partners and funders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Zentek Ltd. (Zentek) (Nasdaq:ZTEK)(TSX-V:ZEN) and 1Click Heating and Cooling Inc. (1Click) have signed a distribution agreement for ZenGUARD™ enhanced viral filtration efficiency MERV 9 rated filters. The agreement capitalizes on the growing global heat pump market, with 1Click positioned to benefit from significant financial incentives for heat pump installations in Canada.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.8%
Tags
none
-
News
Rhea-AI Summary
Zentek Ltd. (ZTEK) grants 400,000 options to a director and officer, exercisable at $1.75 per share, with vesting over three to five years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
Rhea-AI Summary
Zentek Ltd. (ZTEK) announces successful testing of its COVID-19 High-Binding Affinity (C19HBA) aptamer against the Omicron XBB 1.5 variant, showing comparable performance to monoclonal antibodies. The company aims to leverage its platform for the development of new therapeutics, exploring partnership opportunities in the pharmaceutical space.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.54%
Tags
covid-19
-
Rhea-AI Summary
Zentek Ltd. (ZTEK) provides an update on its wholly owned subsidiary Albany Graphite Corp., intending to transfer its Albany Graphite Deposit to a subsidiary and complete a proposed private placement financing. However, due to deteriorating market conditions for battery metals and graphite, the company has decided to wait for improved market conditions before proceeding with the Private Placement and/or Listing. The company continues to believe in the long-term value and potential of the Albany Graphite Deposit, and management intends to continue evaluating potential financing and partnership opportunities. Brian Bosse has ceased to act as the CEO of Albany Graphite Corp., and Greg Fenton has been appointed as the interim CEO. Zentek expects the Albany Graphite Project to combine the higher performance metrics of synthetic graphite with the much lower carbon footprint offered by natural graphite, sourced in North America, to meet the increasing demand for North American sourced graphite.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
none
-
Rhea-AI Summary
Zentek Ltd. (ZTEK) Announces Major Upgrade to Aptamer Platform, Boosting Covid-19 Therapeutic Potential. The company has developed a significant upgrade to its aptamer platform, increasing the binding affinity of the universal Covid-19 aptamer and solving key manufacturing challenges. Zentek's HBA aptamers are now produced with a 95% yield, offering cost-effective and high-purity manufacturing. The company has filed a new provisional patent to protect this latest innovation. Zentek aims to explore oncology and immunology research, leveraging its aptamer platform. The company's HBA aptamer for SARS-CoV-2 has shown strong therapeutic potential and is estimated to require $1.0 million to complete the pre-clinical program and enter clinical trials. Zentek's CEO and Independent Director highlight the promising future of the aptamer platform in drug development and welcome Mr. John Snisarenko to the Board of Directors, bringing significant pharmaceutical industry experience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
Rhea-AI Summary
Zentek Ltd. announces completion of a study on potential savings for the Canadian healthcare system from adopting ZenGUARD-enhanced air filters.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
none
Zentek Ltd

Nasdaq:ZTEK

ZTEK Rankings

ZTEK Stock Data

127.02M
95.27M
5.93%
0.8%
0.09%
Research and Development in Nanotechnology
Professional, Scientific, and Technical Services
Link
Canada
Thunder Bay